The ENTPD1 Gene SPG64 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the ENTPD1 gene, which are associated with Spastic Paraplegia 64 (SPG64). This condition is a form of hereditary spastic paraplegia, characterized by progressive weakness and stiffness of the legs. The test plays a crucial role in the early detection and management of SPG64, enabling healthcare providers to tailor interventions and support to the specific needs of individuals affected by this condition.
The procedure involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic alterations in the ENTPD1 gene. This comprehensive analysis helps in confirming the diagnosis, understanding the disease's progression, and informing potential treatment strategies.
The cost of the ENTPD1 Gene SPG64 Genetic Test at DNA Labs UAE is set at 4400 AED. This investment covers the full spectrum of services, from the initial collection of the sample to the detailed analysis and reporting of results. By choosing DNA Labs UAE for this genetic testing, patients and healthcare providers can expect accurate, reliable, and timely results, aiding in the effective management of Spastic Paraplegia 64.
The ZFYVE26 gene, associated with Spastic Paraplegia 15 (SPG15), is a crucial genetic marker for diagnosing this rare and complex form of hereditary spastic paraplegia. SPG15 is characterized by progressive weakness and stiffness of the legs, and it can also affect the brain and peripheral nervous system, leading to a wide range of symptoms including vision loss, cognitive impairment, and thinning of the corpus callosum. The condition follows an autosomal recessive pattern of inheritance, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
The ZFYVE26 Gene SPG15 Genetic Test is a sophisticated diagnostic tool aimed at detecting mutations in the ZFYVE26 gene, offering crucial information for the diagnosis, management, and genetic counseling of affected individuals and their families. Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, this test represents a critical step towards personalized medicine for patients dealing with SPG15.
The cost of the ZFYVE26 Gene SPG15 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the meticulous process of DNA analysis to identify the presence of mutations associated with the condition. Given the complexity of hereditary spastic paraplegia and the importance of accurate diagnosis for effective management and treatment planning, this test provides invaluable insights for affected individuals and their healthcare providers.
The BSCL2 Gene SPG17 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the BSCL2 gene, which is closely associated with Silver syndrome or distal hereditary motor neuropathy type V (dHMN-V), and a form of spastic paraplegia known as SPG17. This test is crucial for individuals displaying symptoms related to these conditions, as it can confirm the diagnosis and help in tailoring the management and treatment plans accordingly.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample from the patient, usually through a blood draw or cheek swab. The sample is then analyzed using advanced genetic sequencing technologies to detect any abnormalities or mutations in the BSCL2 gene that could lead to the development of the aforementioned neurological disorders.
The cost of the BSCL2 Gene SPG17 Genetic Test at DNA Labs UAE is 4400 AED. This price includes the full process of sample collection, genetic analysis, and a comprehensive report detailing the findings. The report is an essential tool for healthcare providers in making informed decisions regarding the patient's condition and in offering the appropriate genetic counseling for the patient and their family.
Given the complexity of genetic conditions, the BSCL2 Gene SPG17 Genetic Test is a valuable resource for individuals experiencing symptoms of Silver syndrome or SPG17, providing them with critical insights into their genetic makeup and guiding them towards effective management strategies.
The ERLIN2 gene SPG18 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ERLIN2 gene, which are linked to a rare condition known as Spastic Paraplegia 18 (SPG18). This condition is part of a group of hereditary spastic paraplegias, which are characterized by progressive stiffness and contraction (spasticity) in the lower limbs. The ERLIN2 gene plays a crucial role in the functioning of the endoplasmic reticulum, a cell structure involved in protein processing and lipid metabolism. Mutations in this gene can disrupt these processes, leading to the symptoms observed in SPG18.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and comprehensive diagnostic services. By analyzing a patient's DNA, the test can pinpoint specific genetic alterations in the ERLIN2 gene, providing vital information for accurate diagnosis and guiding treatment decisions. This genetic test is particularly important for individuals showing symptoms of spastic paraplegia or those with a family history of the condition, as early detection can significantly impact management and quality of life.
The cost of the ERLIN2 gene SPG18 genetic test at DNA Labs UAE is 4400 AED. This investment covers the technical process of genetic sequencing or analysis, the expertise of genetic counselors and specialists in interpreting the results, and the provision of a detailed report that explains the findings in the context of the patient's health and family history. Given the complexity and specialized nature of this test, it represents a critical step towards personalized medicine for patients affected by or at risk of SPG18.
The PLP1 gene SPG2 genetic test is a specialized diagnostic procedure aimed at detecting mutations in the PLP1 gene, which are associated with Pelizaeus-Merzbacher Disease (PMD) and Spastic Paraplegia Type 2 (SPG2). These conditions are part of a group of genetic disorders known as leukodystrophies, which affect the brain and spinal cord, particularly impacting the myelin sheath that insulates nerve fibers. PMD and SPG2 are characterized by a range of symptoms including motor and cognitive developmental delays, muscle stiffness (spasticity), and involuntary eye movements.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the PLP1 gene SPG2 genetic test provides critical insights for families and healthcare providers. By analyzing an individual's DNA, the test can confirm a diagnosis, guide treatment options, and offer information on the risk of passing the condition to future generations. The cost of the test is set at 4400 AED, reflecting the sophisticated technology and expert analysis involved in identifying the specific genetic mutations out of the vast complexity of the human genome.
This genetic test represents a crucial step for affected families in understanding their condition, enabling informed decisions regarding care and management. It is recommended for individuals showing symptoms of PMD or SPG2, or for those with a family history of these disorders, as early diagnosis can significantly influence the approach to treatment and support.
The SPART Gene SPG20 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the SPG20 gene, which are associated with Troyer syndrome, a form of hereditary spastic paraplegia. This condition is characterized by progressive weakness and stiffness of the legs, developmental delays, and other neurological issues. The test is crucial for individuals with a family history of Troyer syndrome or those presenting symptoms suggestive of hereditary spastic paraplegia, as it aids in confirming the diagnosis, understanding the risk of transmission to offspring, and guiding management and therapeutic interventions. The cost of the SPART Gene SPG20 Genetic Test at DNA Labs UAE is 4400 AED, making it an accessible option for those seeking comprehensive genetic analysis in the region.
The SPG21 gene is associated with a rare disorder known as Mast Syndrome, a form of hereditary spastic paraplegia (HSP). This condition is characterized by progressive weakness and spasticity of the legs, leading to severe mobility issues and other neurological symptoms. The SPG21 genetic test is a crucial diagnostic tool designed to detect mutations in the SPG21 gene, confirming the diagnosis of Mast Syndrome and aiding in the management and treatment planning for affected individuals.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the SPG21 genetic test involves analyzing the patient's DNA to look for specific mutations in the SPG21 gene that are known to cause the disorder. This test is essential for families with a history of Mast Syndrome, as it can provide valuable information for genetic counseling and future family planning.
The cost of the SPG21 genetic test at DNA Labs UAE is 4400 AED. This price includes the full process of sample collection, DNA analysis, and a comprehensive report detailing the results and their implications. Given the complexity of genetic testing and the expertise required to interpret the results accurately, the cost reflects the high level of service and reliability offered by DNA Labs UAE.
In summary, the SPG21 genetic test is a specialized diagnostic tool available at DNA Labs UAE, aimed at individuals and families affected by or at risk of Mast Syndrome. At a cost of 4400 AED, this test offers a pathway to understanding and managing this rare genetic disorder more effectively.
The DDHD1 gene SPG28 genetic test is a specialized diagnostic tool designed to detect mutations in the DDHD1 gene, which are associated with a rare form of hereditary spastic paraplegia (HSP), specifically SPG28. HSPs are a group of inherited disorders characterized by progressive stiffness and contraction (spasticity) in the lower limbs, and SPG28 is one of its autosomal recessive subtypes.
This genetic test involves analyzing the patient's DNA to identify any alterations in the DDHD1 gene that may lead to the disease. It is a crucial step in confirming the diagnosis of SPG28, allowing for a better understanding of the condition, informed genetic counseling, and personalized management plans for affected individuals.
The test is offered by DNA Labs UAE, a leading facility in genetic testing and analysis. The cost of the DDHD1 gene SPG28 genetic test is 4400 AED. DNA Labs UAE employs state-of-the-art technology and follows stringent protocols to ensure the accuracy and reliability of the test results, providing essential insights for patients and their families dealing with the challenges of hereditary spastic paraplegia.
The KIF1A Gene SPG30 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the KIF1A gene, which are associated with SPG30, a form of hereditary spastic paraplegia. This condition affects the nervous system, leading to progressive weakness and stiffness of the legs. The test, priced at 4400 AED, involves analyzing the patient's DNA to detect any genetic alterations in the KIF1A gene, helping in the diagnosis, management, and understanding of the condition. By identifying these genetic mutations, healthcare providers can offer more personalized treatment plans and advice for patients and their families on the prognosis and possible genetic counseling needs.
The REEP1 gene SPG31 genetic test is a specialized diagnostic tool aimed at detecting mutations in the REEP1 gene, which are associated with Spastic Paraplegia 31 (SPG31). SPG31 is a form of hereditary spastic paraplegia, a group of genetic disorders characterized by progressive stiffness and weakness of the legs. Mutations in the REEP1 gene disrupt the normal function of neurons in the spinal cord, leading to the symptoms associated with the condition.
The test is conducted by DNA Labs UAE, a reputable facility known for its comprehensive range of genetic testing services. By analyzing a sample of the patient's DNA, the test can identify specific mutations in the REEP1 gene that are linked to SPG31. This information is crucial for accurate diagnosis, enabling healthcare providers to offer appropriate genetic counseling and tailor management strategies to the individual's needs.
The cost of the REEP1 gene SPG31 genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the REEP1 gene. For patients and families affected by hereditary spastic paraplegia, this test represents a critical step towards understanding their condition and making informed decisions about their care.
